Daily Ards Research Analysis
Three studies advance ARDS science across physiology, therapeutics, and COVID-19 vascular biology. A multicenter Bayesian analysis identifies elastic static power as the ventilatory power component most correlated with ARDS severity; a small clinical series shows ivabradine or beta-blockers can raise the ECMO flow/cardiac output ratio in refractory hypoxemia but at the cost of lower oxygen delivery; and mechanistic work demonstrates sustained endothelial activation by SARS-CoV-2 spike under phys
Summary
Three studies advance ARDS science across physiology, therapeutics, and COVID-19 vascular biology. A multicenter Bayesian analysis identifies elastic static power as the ventilatory power component most correlated with ARDS severity; a small clinical series shows ivabradine or beta-blockers can raise the ECMO flow/cardiac output ratio in refractory hypoxemia but at the cost of lower oxygen delivery; and mechanistic work demonstrates sustained endothelial activation by SARS-CoV-2 spike under physiological flow.
Research Themes
- Ventilator power metrics and ARDS severity
- Hemodynamic modulation during VV-ECMO for refractory hypoxemia
- Endothelial inflammation and COVID-19-related ARDS pathophysiology
Selected Articles
1. Elastic static power, its correlation with acute respiratory distress syndrome severity: A Bayesian post-hoc analysis of the Mechanical Power Day cross-sectional trial.
In a multicenter Bayesian post-hoc analysis of the Mechanical Power Day cross-sectional cohort, elastic static power showed the strongest independent correlation with ARDS severity compared with other mechanical power components. Values increased from 5.8 J/min in mild ARDS to 7.4 J/min in moderate/severe ARDS, with posterior means indicating stronger associations.
Impact: Identifying elastic static power as the most severity-linked power component refines ventilatory risk stratification and may guide personalized ventilation strategies in ARDS.
Clinical Implications: Elastic static power could be prioritized for bedside monitoring and ventilator adjustments to mitigate ventilator-induced lung injury and to stratify ARDS severity. Thresholds linked to outcomes warrant prospective evaluation.
Key Findings
- Elastic static power was 5.8 J/min in mild ARDS and 7.4 J/min in moderate/severe ARDS.
- Bayesian regression showed independent correlations for mild (posterior mean 1.3; 95% CrI 0.2-2.2) and moderate/severe ARDS (posterior mean 2.8; 95% CrI 1.7-3.8), stronger than other power equations.
- Analysis spanned 113 ICUs across 15 countries, increasing generalizability.
Methodological Strengths
- Large, multinational multicenter dataset (113 ICUs across 4 continents)
- Bayesian modeling with a priori distributions to quantify uncertainty
Limitations
- Post-hoc analysis of cross-sectional data limits causal inference
- Potential confounding by ventilator settings and unmeasured clinical factors; prospective validation lacking
Future Directions: Prospective studies to validate elastic static power thresholds, assess outcome associations, and test ventilation strategies targeting reductions in elastic static power.
OBJECTIVE: The relationship between different power equations and the severity of acute respiratory distress syndrome (ARDS) remains unclear. This study aimed to evaluate various power equations: total mechanical power, total elastic power (comprising elastic static and elastic dynamic power), and resistive power, in a cohort of mechanically ventilated patients with and without ARDS. Bayesian analysis was employed to refine estimates and quantify uncertainty by incorporating a priori distributions. DESIGN: A Bayesian post-hoc analysis was conducted on data from the Mechanical Power Day study. SETTING: 113 intensive care units across 15 countries and 4 continents. PATIENTS: Adults who received invasive mechanical ventilation in volume-controlled mode, with (mild and moderate/severe ARDS) and without ARDS. INTERVENTIONS: None. MAIN VARIABLES OF INTEREST: ARDS, Elastic static power. RESULTS: Elastic static power was 5.8 J/min (BF: 0.3) in patients with mild ARDS and 7.4 J/min (BF: 0.9) in moderate/severe ARDS patients. Bayesian regression and modeling analysis revealed that elastic static power was independently correlated with mild (a posteriori Mean: 1.3; 95% Credible Interval [Cred. Interval]: 0.2-2.2) and moderate/severe ARDS (a posteriori Mean: 2.8; 95% Cred. Interval: 1.7-3.8) more strongly than other power equations. CONCLUSIONS: Elastic static power was found to have the strongest correlation with ARDS severity among the power equations studied. Prospective studies are needed to further validate these findings.
2. Sustained Vascular Inflammatory Effects of SARS-CoV-2 Spike Protein on Human Endothelial Cells.
Under physiological flow, SARS-CoV-2 spike protein induced sustained endothelial activation in both aortic and pulmonary microvascular endothelial cells, including prolonged adhesion molecule expression, cytokine/chemokine release, leukocyte binding, and a procoagulant state. Transcriptomics revealed persistent upregulation of antiviral, cytokine, pattern-recognition, complement, and coagulation pathways.
Impact: This study mechanistically links SARS-CoV-2 spike to prolonged endothelial dysfunction relevant to ARDS and post-acute sequelae, highlighting endothelial protection as a therapeutic strategy.
Clinical Implications: Supports evaluating endothelial-protective and anticoagulant/anti-inflammatory strategies in COVID-19-related ARDS and post-acute sequelae. Biomarker development targeting endothelial activation pathways may aid risk stratification.
Key Findings
- SARS-CoV-2 spike triggered prolonged adhesion molecule expression in both HAoEC and HPMC, akin to TNF-α effects.
- Spike exposure led to cytokine/chemokine release, increased leukocyte binding, and a procoagulant endothelial state.
- Transcriptomics under flow showed persistent upregulation of antiviral, cytokine-mediated, pattern recognition, complement, and coagulation pathways.
Methodological Strengths
- Physiological flow culture conditions better mimic in vivo hemodynamics
- Use of two endothelial cell types (aortic and pulmonary microvascular) plus transcriptomic profiling
Limitations
- In vitro study without in vivo validation; clinical dosing/exposure not directly modeled
- Use of spike protein rather than whole virus; translation to clinical outcomes requires further study
Future Directions: Validate findings in in vivo models and patient samples; test endothelial-stabilizing interventions and link endothelial activation signatures with ARDS severity and long COVID outcomes.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been associated with systemic inflammation and vascular injury, which contribute to the development of acute respiratory syndrome (ARDS) and the mortality of COVID-19 infection. Moreover, multiorgan complications due to persistent endothelial dysfunction have been suspected as the cause of post-acute sequelae of SARS-CoV-2 infection. Therefore, elucidation of the vascular inflammatory effect of SARS-CoV-2 will increase our understanding of how endothelial cells (ECs) contribute to the short- and long-term consequences of SARS-CoV-2 infection. Here, we investigated the interaction of SARS-CoV-2 spike protein with human ECs from aortic (HAoEC) and pulmonary microvascular (HPMC) origins, cultured under physiological flow conditions. We showed that the SARS-CoV-2 spike protein triggers prolonged expression of cell adhesion markers in both ECs, similar to the effect of TNF-α. SARS-CoV-2 spike treatment also led to the release of various cytokines and chemokines observed in severe COVID-19 patients. Moreover, increased binding of leucocytes to the endothelial surface and a procoagulant state of the endothelium were observed. Transcriptomic profiles of SARS-CoV-2 spike-activated HPMC and HAoEC showed prolonged upregulation of genes and pathways associated with responses to virus, cytokine-mediated signaling, pattern recognition, as well as complement and coagulation pathways. Our findings support experimental and clinical observations of the vascular consequences of SARS-CoV-2 infection and highlight the importance of EC protection as one of the strategies to mitigate the severe effects as well as the possible post-acute complications of COVID-19 disease.
3. Control of Cardiac Output with Ivabradine or Beta-Blockers for Refractory Hypoxemia under Veno-Venous ECMO for Severe ARDS.
In a retrospective series of 10 refractory hypoxemia cases under VV-ECMO for severe ARDS, ivabradine and/or short-acting beta-blockers increased the ECMO flow/cardiac output ratio from 60% to 69% (p=0.02). While tolerated and sometimes improving arterial oxygenation, this approach was associated with decreased systemic oxygen delivery.
Impact: Introduces a pharmacologic strategy to modulate cardiac output during VV-ECMO, a critical and understudied lever for refractory hypoxemia management, while highlighting safety trade-offs.
Clinical Implications: CO-slowing with ivabradine or beta-blockers can increase the ECMO flow fraction, potentially improving SaO2, but may reduce DO2. If considered, use individualized protocols with continuous hemodynamic and oxygen delivery monitoring.
Key Findings
- Among 70 VV-ECMO patients, 10 with refractory hypoxemia received CO control with ivabradine and/or short-acting beta-blockers.
- ECMO flow/CO ratio increased from 60% [50-66] to 69% [61-81] overall (p=0.02), and improved with each agent individually.
- Improved arterial oxygenation was associated with decreased oxygen delivery (DO2), underscoring a safety trade-off.
Methodological Strengths
- Consecutive-case retrospective analysis during a defined period in a tertiary center
- Direct hemodynamic metric (ECMO flow/CO ratio) with pre/post comparisons
Limitations
- Small single-center series (n=10) without a control group; potential confounding
- Incomplete reporting of full oxygenation metrics in abstract; short-term outcomes only
Future Directions: Prospective controlled studies to define safety thresholds, identify responders, and integrate continuous DO2 and tissue oxygenation monitoring into CO-modulation protocols during VV-ECMO.
PURPOSE: Hypoxemia is a risk factor for mortality and long-term neuropsychological impairment during severe acute respiratory distress syndrome (ARDS). Veno-venous extracorporeal membrane oxygenation (VV-ECMO) is a potential treatment for such cases but may not suffice. We aimed to evaluate the effects of pharmacological interventions for cardiac output (CO) control using ivabradine or beta-blockers for refractory hypoxemia during VV-ECMO. METHODS: The study involved retrospective analysis of consecutive patients with severe ARDS who underwent VV-ECMO at a tertiary university hospital between March 2020 and May 2022. Patients with refractory hypoxemia under VV-ECMO were included. Pharmacological interventions included ivabradine and/or short half-life beta-blockers. The primary endpoint was the change in ECMO flow/CO ratio and secondary endpoints were changes in macrocirculation (mean arterial pressure), oxygenation [arterial saturation (SaO RESULTS: Out of 70 patients on VV-ECMO, ten had refractory hypoxemia under VV-ECMO and received pharmacological interventions to control CO. The ECMO flow/CO ratio significantly increased with pharmacological intervention overall (from 60% [50-66] to 69% [61-81], p = 0.02), as well as with beta-blockers or ivabradine individually. However, DO CONCLUSION: Ivabradine and beta-blockers were clinically well-tolerated and improved the ECMO flow/CO ratio in patients with refractory hypoxemia during VV-ECMO. However, the improvement of arterial oxygenation was associated with decreased DO